JP2018534933A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018534933A5 JP2018534933A5 JP2018522685A JP2018522685A JP2018534933A5 JP 2018534933 A5 JP2018534933 A5 JP 2018534933A5 JP 2018522685 A JP2018522685 A JP 2018522685A JP 2018522685 A JP2018522685 A JP 2018522685A JP 2018534933 A5 JP2018534933 A5 JP 2018534933A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- heavy chain
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 222
- 230000027455 binding Effects 0.000 claims description 134
- 239000012634 fragment Substances 0.000 claims description 128
- 101000960952 Homo sapiens Interleukin-1 receptor accessory protein Proteins 0.000 claims description 109
- 102100039880 Interleukin-1 receptor accessory protein Human genes 0.000 claims description 105
- 206010028980 Neoplasm Diseases 0.000 claims description 47
- 239000000427 antigen Substances 0.000 claims description 46
- 102000036639 antigens Human genes 0.000 claims description 46
- 108091007433 antigens Proteins 0.000 claims description 46
- 210000004027 cell Anatomy 0.000 claims description 46
- 201000011510 cancer Diseases 0.000 claims description 43
- 238000000034 method Methods 0.000 claims description 38
- 150000001413 amino acids Chemical class 0.000 claims description 28
- 239000008194 pharmaceutical composition Substances 0.000 claims description 26
- 238000006467 substitution reaction Methods 0.000 claims description 14
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 6
- 229940124597 therapeutic agent Drugs 0.000 claims description 6
- 230000002401 inhibitory effect Effects 0.000 claims description 5
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims description 4
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims description 4
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 4
- 206010009944 Colon cancer Diseases 0.000 claims description 4
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 4
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims description 4
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims description 4
- 208000000389 T-cell leukemia Diseases 0.000 claims description 4
- 208000028530 T-cell lymphoblastic leukemia/lymphoma Diseases 0.000 claims description 4
- 206010042971 T-cell lymphoma Diseases 0.000 claims description 4
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 claims description 4
- 239000002246 antineoplastic agent Substances 0.000 claims description 4
- 229940127089 cytotoxic agent Drugs 0.000 claims description 4
- 102000046828 human IL1RAP Human genes 0.000 claims description 4
- 210000004408 hybridoma Anatomy 0.000 claims description 4
- 201000005202 lung cancer Diseases 0.000 claims description 4
- 208000020816 lung neoplasm Diseases 0.000 claims description 4
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 claims description 4
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims description 3
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 3
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 3
- 201000002528 pancreatic cancer Diseases 0.000 claims description 3
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 3
- 230000035755 proliferation Effects 0.000 claims description 3
- 208000003950 B-cell lymphoma Diseases 0.000 claims description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 2
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical group O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 claims description 2
- 208000017815 Dendritic cell tumor Diseases 0.000 claims description 2
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims description 2
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims description 2
- 102000000588 Interleukin-2 Human genes 0.000 claims description 2
- 108010002350 Interleukin-2 Proteins 0.000 claims description 2
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims description 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims description 2
- 102000003945 NF-kappa B Human genes 0.000 claims description 2
- 108010057466 NF-kappa B Proteins 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
- 230000033115 angiogenesis Effects 0.000 claims description 2
- 229940045799 anthracyclines and related substance Drugs 0.000 claims description 2
- 238000011394 anticancer treatment Methods 0.000 claims description 2
- 208000029742 colonic neoplasm Diseases 0.000 claims description 2
- 238000012258 culturing Methods 0.000 claims description 2
- 229960000684 cytarabine Drugs 0.000 claims description 2
- 230000003013 cytotoxicity Effects 0.000 claims description 2
- 231100000135 cytotoxicity Toxicity 0.000 claims description 2
- 230000001419 dependent effect Effects 0.000 claims description 2
- 230000000779 depleting effect Effects 0.000 claims description 2
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 229960004931 histamine dihydrochloride Drugs 0.000 claims description 2
- PPZMYIBUHIPZOS-UHFFFAOYSA-N histamine dihydrochloride Chemical compound Cl.Cl.NCCC1=CN=CN1 PPZMYIBUHIPZOS-UHFFFAOYSA-N 0.000 claims description 2
- 238000000338 in vitro Methods 0.000 claims description 2
- 230000001404 mediated effect Effects 0.000 claims description 2
- 238000001565 modulated differential scanning calorimetry Methods 0.000 claims description 2
- 210000004985 myeloid-derived suppressor cell Anatomy 0.000 claims description 2
- 210000005134 plasmacytoid dendritic cell Anatomy 0.000 claims description 2
- 102000040430 polynucleotide Human genes 0.000 claims description 2
- 108091033319 polynucleotide Proteins 0.000 claims description 2
- 239000002157 polynucleotide Substances 0.000 claims description 2
- 230000011664 signaling Effects 0.000 claims description 2
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 1
- 230000009977 dual effect Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000009870 specific binding Effects 0.000 claims 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562249466P | 2015-11-02 | 2015-11-02 | |
| US62/249,466 | 2015-11-02 | ||
| PCT/US2016/059842 WO2017079121A2 (en) | 2015-11-02 | 2016-11-01 | Anti-il1rap antibodies, bispecific antigen binding molecules that bind il1rap and cd3, and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018534933A JP2018534933A (ja) | 2018-11-29 |
| JP2018534933A5 true JP2018534933A5 (OSRAM) | 2019-12-05 |
Family
ID=57286884
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018522685A Pending JP2018534933A (ja) | 2015-11-02 | 2016-11-01 | 抗ｉｌ１ｒａｐ抗体、ｉｌ１ｒａｐとｃｄ３を結合する二重特異性抗原結合分子、及びその使用 |
Country Status (25)
| Country | Link |
|---|---|
| US (2) | US20170121420A1 (OSRAM) |
| EP (1) | EP3371220A2 (OSRAM) |
| JP (1) | JP2018534933A (OSRAM) |
| KR (1) | KR20180072820A (OSRAM) |
| CN (1) | CN108431042A (OSRAM) |
| AR (1) | AR106555A1 (OSRAM) |
| AU (1) | AU2016350705A1 (OSRAM) |
| BR (1) | BR112018008908A2 (OSRAM) |
| CA (1) | CA3003899A1 (OSRAM) |
| CL (1) | CL2018001175A1 (OSRAM) |
| CO (1) | CO2018005695A2 (OSRAM) |
| CR (1) | CR20180250A (OSRAM) |
| EA (1) | EA201891084A1 (OSRAM) |
| EC (1) | ECSP18040535A (OSRAM) |
| IL (1) | IL259082A (OSRAM) |
| JO (1) | JO3800B1 (OSRAM) |
| MA (1) | MA43164A (OSRAM) |
| MX (1) | MX2018005545A (OSRAM) |
| NI (1) | NI201800057A (OSRAM) |
| PE (1) | PE20181310A1 (OSRAM) |
| PH (1) | PH12018500938A1 (OSRAM) |
| SG (1) | SG11201803675RA (OSRAM) |
| TW (1) | TW201734045A (OSRAM) |
| UY (1) | UY36974A (OSRAM) |
| WO (1) | WO2017079121A2 (OSRAM) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2472856B (en) | 2009-08-21 | 2012-07-11 | Cantargia Ab | IL1-RAP modulators and uses thereof |
| EP3508498A1 (en) | 2011-01-19 | 2019-07-10 | Cantargia AB | Novel agents and uses thereof |
| GB201403875D0 (en) | 2014-03-05 | 2014-04-16 | Cantargia Ab | Novel antibodies and uses thereof |
| GB201413913D0 (en) | 2014-08-06 | 2014-09-17 | Cantargia Ab | Novel antibodies and uses thereof |
| US10202365B2 (en) | 2015-02-06 | 2019-02-12 | Blueprint Medicines Corporation | 2-(pyridin-3-yl)-pyrimidine derivatives as RET inhibitors |
| EA039859B1 (ru) | 2015-07-31 | 2022-03-21 | Эмджен Рисерч (Мюник) Гмбх | Биспецифические конструкты антител, связывающие egfrviii и cd3 |
| TWI829617B (zh) | 2015-07-31 | 2024-01-21 | 德商安美基研究（慕尼黑）公司 | Ｆｌｔ３及ｃｄ３抗體構築體 |
| TWI744242B (zh) | 2015-07-31 | 2021-11-01 | 德商安美基研究（慕尼黑）公司 | Egfrviii及cd3抗體構築體 |
| TWI796283B (zh) | 2015-07-31 | 2023-03-21 | 德商安美基研究（慕尼黑）公司 | Ｍｓｌｎ及ｃｄ３抗體構築體 |
| EA038890B1 (ru) | 2015-11-02 | 2021-11-03 | Блюпринт Медсинс Корпорейшн | Ингибиторы ret |
| EP3370771A4 (en) * | 2015-11-03 | 2019-06-19 | Ambrx, Inc. | ANTI-CD3-FOLAT-CONJUGATES AND ITS USES |
| LT3411404T (lt) | 2016-02-03 | 2022-12-27 | Amgen Research (Munich) Gmbh | Psma ir cd3 bispecifiniai, t ląsteles aktyvuojantys antikūno konstruktai |
| TWI781108B (zh) | 2016-07-20 | 2022-10-21 | 比利時商健生藥品公司 | 抗ｇｐｒｃ５ｄ抗體、結合ｇｐｒｃ５ｄ與ｃｄ３之雙特異性抗原結合分子及其用途 |
| JOP20190097A1 (ar) | 2016-10-27 | 2019-04-28 | Janssen Pharmaceutica Nv | الجلوبولينات المناعية واستخداماتها |
| CA3044682A1 (en) | 2016-12-02 | 2018-06-07 | University Of Southern California | Synthetic immune receptors and methods of use thereof |
| EP3824906A1 (en) | 2016-12-21 | 2021-05-26 | Amgen Inc. | Anti-tnf alpha antibody formulations |
| CN118994394A (zh) * | 2017-06-12 | 2024-11-22 | 蓝鳍生物医药公司 | 抗-il1rap抗体和抗体药物缀合物 |
| EP3661558A4 (en) | 2017-08-01 | 2021-08-11 | City of Hope | ANTI-IL1RAP ANTIBODIES |
| EP3489259A1 (en) * | 2017-11-23 | 2019-05-29 | Etablissement Français du Sang | Anti-il-1rap-car-t cells and their use |
| CA3096043A1 (en) | 2018-04-03 | 2019-10-10 | Blueprint Medicines Corporation | Ret inhibitor for use in treating cancer having a ret alteration |
| RS66901B1 (sr) | 2018-05-24 | 2025-07-31 | Janssen Biotech Inc | Anti-cd3 antitela i njihova upotreba |
| WO2020035577A1 (en) * | 2018-08-16 | 2020-02-20 | Cantargia Ab | Anti-il1rap antibody compositions |
| TW202021618A (zh) | 2018-08-17 | 2020-06-16 | 美商２３與我有限公司 | 抗ｉｌ１ｒａｐ抗體及其使用方法 |
| BR112021010374A2 (pt) * | 2018-12-21 | 2021-08-24 | 23Andme, Inc. | Anticorpos anti-il-36 e métodos de uso dos mesmos |
| BR112021023048A2 (pt) | 2019-05-21 | 2022-04-19 | Novartis Ag | Moléculas de ligação a cd19 e usos das mesmas |
| BR112021025476A2 (pt) | 2019-06-26 | 2022-10-11 | Glaxosmithkline Ip Dev Ltd | Proteínas de ligação à il1rap |
| KR20230017841A (ko) | 2020-05-27 | 2023-02-06 | 얀센 바이오테크 인코포레이티드 | Cd3 항원 결합 도메인을 포함하는 단백질 및 이의 용도 |
| KR20230017234A (ko) | 2020-05-29 | 2023-02-03 | 블루프린트 메디신즈 코포레이션 | 프랄세티닙의 고체 형태 |
| JP2023541627A (ja) | 2020-09-14 | 2023-10-03 | イシュノス サイエンシズ ソシエテ アノニム | Ｉｌ１ｒａｐに結合する抗体及びその使用 |
| JP2024505674A (ja) * | 2021-02-05 | 2024-02-07 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 抗ｉｌ１ｒａｐ抗体 |
| AR130550A1 (es) * | 2022-09-21 | 2024-12-18 | Sanofi Biotechnology | Anticuerpo anti-il-1r3 humanizado y métodos de uso |
| CN116574189A (zh) * | 2023-01-30 | 2023-08-11 | 北京智仁美博生物科技有限公司 | 针对人il-36r和/或人il-1r3的多种抗体及其用途 |
| US12258396B1 (en) * | 2024-02-02 | 2025-03-25 | Medicovestor, Inc. | Methods of using immunotherapeutics that bind folate receptor alpha |
| WO2025201513A1 (zh) * | 2024-03-29 | 2025-10-02 | 珠海丹序生物制药有限公司 | 抗il1rap抗体及其用途 |
| WO2025209480A1 (zh) * | 2024-04-02 | 2025-10-09 | 福佑泰生物制药公司 | 抗il1rap抗体以及其用途 |
| CN119371547B (zh) * | 2024-12-05 | 2025-11-28 | 深圳市艾伟迪生物科技有限公司 | 一种抗nRNP/Sm抗体或其抗原结合片段及其应用 |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69841578D1 (de) | 1997-09-16 | 2010-05-06 | Centocor Inc | Methoden zur kompletten chemischen Synthese und Zusammensetzung von Genen und Genomen |
| US6670127B2 (en) | 1997-09-16 | 2003-12-30 | Egea Biosciences, Inc. | Method for assembly of a polynucleotide encoding a target polypeptide |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| US20020142000A1 (en) | 1999-01-15 | 2002-10-03 | Digan Mary Ellen | Anti-CD3 immunotoxins and therapeutic uses therefor |
| CA2577082A1 (en) | 2004-09-02 | 2006-03-16 | Genentech, Inc. | Heteromultimeric molecules |
| JP5620626B2 (ja) | 2005-03-31 | 2014-11-05 | 中外製薬株式会社 | 会合制御によるポリペプチド製造方法 |
| DE102005028778A1 (de) | 2005-06-22 | 2006-12-28 | SUNJÜT Deutschland GmbH | Mehrlagige Folie mit einer Barriere- und einer antistatischen Lage |
| ES2856451T3 (es) | 2005-10-11 | 2021-09-27 | Amgen Res Munich Gmbh | Composiciones que comprenden anticuerpos específicos para diferentes especies, y usos de las mismas |
| US10155816B2 (en) | 2005-11-28 | 2018-12-18 | Genmab A/S | Recombinant monovalent antibodies and methods for production thereof |
| WO2007147901A1 (en) | 2006-06-22 | 2007-12-27 | Novo Nordisk A/S | Production of bispecific antibodies |
| AU2008234019B2 (en) | 2007-04-03 | 2014-05-29 | Amgen Research (Munich) Gmbh | Cross-species-specific bispecific binders |
| KR101589759B1 (ko) | 2007-04-03 | 2016-01-29 | 암젠 리서치 (뮌헨) 게엠베하 | 종간 특이적 ｃｄ３―입실론 결합 도메인 |
| PT2155783E (pt) | 2007-04-03 | 2013-11-07 | Amgen Res Munich Gmbh | Domínio de ligação específico inter-espécies |
| ES2564523T3 (es) | 2007-12-19 | 2016-03-23 | Janssen Biotech, Inc. | Diseño y generación de bibliotecas de presentación en fago por pIX de novo humanas mediante fusión con pIX o pVII, vectores, anticuerpos y métodos |
| WO2009120905A2 (en) | 2008-03-26 | 2009-10-01 | Cellerant Therapeutics, Inc. | Immunoglobulin and/or toll-like receptor proteins associated with myelogenous haematological proliferative disorders and uses thereof |
| BRPI0919841A2 (pt) | 2008-10-01 | 2014-11-18 | Micromet Ag | Anticorpo de cadeia unica biespecifico de psmaxcd3, especifico de especies cruzadas |
| EP2352763B2 (en) | 2008-10-01 | 2022-09-21 | Amgen Research (Munich) GmbH | Bispecific single chain antibodies with specificity for high molecular weight target antigens |
| AU2009299794B2 (en) | 2008-10-01 | 2015-08-13 | Amgen Research (Munich) Gmbh | Cross-species-specific single domain bispecific single chain antibody |
| CN102307896B (zh) | 2008-10-31 | 2016-10-12 | 森托科尔奥索生物科技公司 | 基于iii型纤连蛋白结构域的支架组合物、方法及用途 |
| CA2752211C (en) | 2009-02-12 | 2020-03-24 | Janssen Biotech, Inc. | Fibronectin type iii domain based scaffold compositions, methods and uses |
| CN102459346B (zh) | 2009-04-27 | 2016-10-26 | 昂考梅德药品有限公司 | 制造异源多聚体分子的方法 |
| GB2472856B (en) * | 2009-08-21 | 2012-07-11 | Cantargia Ab | IL1-RAP modulators and uses thereof |
| CN110066339A (zh) | 2010-04-20 | 2019-07-30 | 根马布股份公司 | 含异二聚体抗体fc的蛋白及其制备方法 |
| RU2604490C2 (ru) | 2010-11-05 | 2016-12-10 | Займворкс Инк. | ДИЗАЙН УСТОЙЧИВОГО ГЕТЕРОДИМЕРНОГО АНТИТЕЛА С МУТАЦИЯМИ В Fc ДОМЕНЕ |
| EP3508498A1 (en) * | 2011-01-19 | 2019-07-10 | Cantargia AB | Novel agents and uses thereof |
| KR102052774B1 (ko) | 2011-11-04 | 2019-12-04 | 자임워크스 인코포레이티드 | Ｆｃ 도메인 내의 돌연변이를 갖는 안정한 이종이합체 항체 설계 |
| PT2931030T (pt) | 2012-12-14 | 2020-08-03 | Open Monoclonal Tech Inc | Polinucleótidos que codificam anticorpos de roedores com idiótipos humanos e animais que os compreendem |
| US20150315279A1 (en) | 2012-12-21 | 2015-11-05 | Cellerant Therapeutics, Inc. | Antibodies that bind membrane-bound il1rap |
| GB201403875D0 (en) * | 2014-03-05 | 2014-04-16 | Cantargia Ab | Novel antibodies and uses thereof |
-
2016
- 2016-11-01 EP EP16794880.1A patent/EP3371220A2/en not_active Withdrawn
- 2016-11-01 CA CA3003899A patent/CA3003899A1/en not_active Abandoned
- 2016-11-01 KR KR1020187015367A patent/KR20180072820A/ko not_active Withdrawn
- 2016-11-01 EA EA201891084A patent/EA201891084A1/ru unknown
- 2016-11-01 CN CN201680077315.3A patent/CN108431042A/zh active Pending
- 2016-11-01 PE PE2018000723A patent/PE20181310A1/es unknown
- 2016-11-01 JP JP2018522685A patent/JP2018534933A/ja active Pending
- 2016-11-01 AU AU2016350705A patent/AU2016350705A1/en not_active Abandoned
- 2016-11-01 SG SG11201803675RA patent/SG11201803675RA/en unknown
- 2016-11-01 BR BR112018008908A patent/BR112018008908A2/pt not_active Application Discontinuation
- 2016-11-01 MX MX2018005545A patent/MX2018005545A/es unknown
- 2016-11-01 MA MA043164A patent/MA43164A/fr unknown
- 2016-11-01 CR CR20180250A patent/CR20180250A/es unknown
- 2016-11-01 US US15/340,149 patent/US20170121420A1/en not_active Abandoned
- 2016-11-01 WO PCT/US2016/059842 patent/WO2017079121A2/en not_active Ceased
- 2016-11-02 JO JOP/2016/0235A patent/JO3800B1/ar active
- 2016-11-02 TW TW105135526A patent/TW201734045A/zh unknown
- 2016-11-02 AR ARP160103340A patent/AR106555A1/es unknown
- 2016-11-03 UY UY0001036974A patent/UY36974A/es unknown
-
2018
- 2018-05-01 IL IL259082A patent/IL259082A/en unknown
- 2018-05-02 CL CL2018001175A patent/CL2018001175A1/es unknown
- 2018-05-02 NI NI201800057A patent/NI201800057A/es unknown
- 2018-05-02 PH PH12018500938A patent/PH12018500938A1/en unknown
- 2018-05-29 EC ECIEPI201840535A patent/ECSP18040535A/es unknown
- 2018-05-30 CO CONC2018/0005695A patent/CO2018005695A2/es unknown
-
2019
- 2019-03-20 US US16/358,894 patent/US20190270826A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018534933A5 (OSRAM) | ||
| JP2017529838A5 (OSRAM) | ||
| IL276830B2 (en) | Anti-claudin 18.2 antibodies and uses thereof | |
| JP2021184721A5 (OSRAM) | ||
| RU2019111722A (ru) | Антитела против siglec-15 и способы их применения | |
| JP2013543498A5 (OSRAM) | ||
| JP2017510559A5 (OSRAM) | ||
| FI3487882T3 (fi) | Gprc5d-vasta-aineita, bispesifisiä antigeeniä sitovia molekyylejä, jotka sitovat gprc5d:tä ja cd3:a, sekä niiden käyttötapoja | |
| JP2020514310A5 (OSRAM) | ||
| JP2020520370A5 (OSRAM) | ||
| JP2019532056A5 (OSRAM) | ||
| JP2017514461A5 (OSRAM) | ||
| ME02148B (me) | Notch-vezivni agensi i antagonisti i postupci za njihovo korišćenje | |
| JP2019500893A5 (OSRAM) | ||
| JP2017535257A5 (OSRAM) | ||
| FI3394103T3 (fi) | Anti-PD-1-vasta-aineiden ja bispesifisten anti-CD20-/anti-CD3-vasta-aineiden yhdistelmä syövän hoitoon | |
| JPWO2019224711A5 (OSRAM) | ||
| JP2016532688A5 (OSRAM) | ||
| JP2020522281A5 (OSRAM) | ||
| JP2020522280A5 (OSRAM) | ||
| JP2017522861A5 (OSRAM) | ||
| JP2010520290A5 (OSRAM) | ||
| RU2019139093A (ru) | Фармацевтическая композиция на основе антитела к pd-l1 и ее применение | |
| JP2020515577A5 (OSRAM) | ||
| CN111246881A (zh) | Pd-1抗体用于治疗肿瘤的用途 |